Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats acute myeloid leukemia (AML) Reduce the duration of neutropenia and…. Sold as Neupogen. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Filgrastim (sold as Neupogen), first approved Feb 20, 1991, with 5 new uses approved and 0 published complete response letters.
First approved: Feb 20, 1991
Applications: 1
New uses approved: 5
Complete response letters: 0
Medicare spending, 2025: $14.4M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Neupogen
Part B
$7.4M
-26%
3,162
Neupogen
Part D
$7.1M
-2%
990
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
NEUPOGEN 300 MCG/0.5 ML SYR: $650.05 per MLBrand · 0% in a year
NEUPOGEN 300 MCG/ML VIAL: $304.09 per MLBrand · 0% in a year
GranDrugs with a new indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute… · Kyowa Kirin Co., Ltd. · Jun 20, 2022
GranDrugs with a new indication and a new dosage for the enhancement of an antitumor effect of dinutuximab (genetical recombination) for neuroblastoma. · Kyowa Kirin Co., Ltd. · Jun 23, 2021
Clinical Trials
229 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Amgen